Why the study?
Alpha-blockers have been associated with orthostatic hypotension, but data using beat-to-beat blood pressure monitoring in older males treated for lower urinary tract symptoms were needed.
Does alpha-blocker use for lower urinary tract symptoms increase the risk of orthostatic hypotension in older males?
Does alpha-blocker use for lower urinary tract symptoms increase the risk of orthostatic hypotension in older males?
While overall orthostatic hypotension prevalence is low in older men taking alpha-blockers for LUTS, the risk is significantly elevated in those with multimorbidity or polypharmacy, warranting careful risk-benefit assessment.
OH risk may warrant caution in multimorbid or polypharmacy patients on alpha-blockers; leaves open causal effects and optimal mitigation.
WHAT IS KNOWN AND OBJECTIVE: Alpha-blockers have been associated with orthostatic hypotension (OH). We aimed to assess the prevalence of OH measured with beat-to-beat blood pressure monitoring in older male outpatients who used alpha-blockers for lower urinary tract symptoms (LUTS). In addition, we investigated associations of OH with duration of alpha-blocker use, concomitant medication use and comorbidity. METHODS: Cross-sectional explorative study in a urology outpatient clinic. Older white males ≥65 years using alpha-blockers for LUTS were included. Blood pressure responses to standing up from supine were recorded using a validated beat-to-beat blood pressure device (Finapres). Prevalence rates were derived from the beat-to-beat data to include OH measured between 60-110 s (OH), impaired recovery OH at 40 s (OH[40]), initial OH (IOH) and normal orthostatic response. Subgroups were defined based on duration of alpha-blocker use, polypharmacy, and Charlson comorbidity index (CCI), to obtain relative risks. RESULTS AND DISCUSSION: 10 medications (n = 13) was 6.0 (95%CI 1.1-32.3). For the subgroup with multimorbidity (CCI ≥3, n = 11) this was 7.4 (95%CI 1.4-39.0). Recent initiation of alpha-blocker use (<3 months) did not increase OH risk (RR 0.6 [95%CI 0.1-5.1]). WHAT IS NEW AND CONCLUSION: The overall prevalence of OH was low and comparable to age-matched population prevalence, suggesting that the relative contribution of alpha-blockers to OH was small. However, OH risk significantly increased in patients with multimorbidity or polypharmacy. For these patients, the benefits of starting alpha-blockers for LUTS should be weighed against the increased risk of OH.
No takes yet. Share an insight, caveat, or question.
Spies et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: